ConductScience.org, home
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
API referenceFor AI assistants

Trial · NCT02432274

Participant flow40

How many started, completed or left each group, period by period.

1 to 20 of 40

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDCohort 1, Single-agent Dose-finding: Lenvatinib 11 mg/m^23
Overall StudySTARTEDCohort 1, Single-agent Dose-finding: Lenvatinib 14 mg/m^29
Overall StudySTARTEDCohort 1, Single-agent Dose-finding: Lenvatinib 17 mg/m^211
Overall StudySTARTEDCohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^21
Overall StudySTARTEDCohort2B,Single-agentExpansion,Osteosarcoma:Lenvatinib14mg/m^231
Overall StudySTARTEDCohort 3A, Combination Dose-finding: Lenvatinib 11 mg/m^27
Overall StudySTARTEDCohort 3A, Combination Dose-finding: Lenvatinib 14 mg/m^215
Overall StudySTARTEDCohort 3B, Combination Expansion: Lenvatinib 14 mg/m^220
Overall StudyUnderwent Run-in PeriodCohort 1, Single-agent Dose-finding: Lenvatinib 11 mg/m^21
Overall StudyUnderwent Run-in PeriodCohort 1, Single-agent Dose-finding: Lenvatinib 14 mg/m^21
Overall StudyUnderwent Run-in PeriodCohort 1, Single-agent Dose-finding: Lenvatinib 17 mg/m^20
Overall StudyUnderwent Run-in PeriodCohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^20
Overall StudyUnderwent Run-in PeriodCohort2B,Single-agentExpansion,Osteosarcoma:Lenvatinib14mg/m^20
Overall StudyUnderwent Run-in PeriodCohort 3A, Combination Dose-finding: Lenvatinib 11 mg/m^20
Overall StudyUnderwent Run-in PeriodCohort 3A, Combination Dose-finding: Lenvatinib 14 mg/m^20
Overall StudyUnderwent Run-in PeriodCohort 3B, Combination Expansion: Lenvatinib 14 mg/m^20
Overall StudyTreated (Safety Population)Cohort 1, Single-agent Dose-finding: Lenvatinib 11 mg/m^25
Overall StudyTreated (Safety Population)Cohort 1, Single-agent Dose-finding: Lenvatinib 14 mg/m^211
Overall StudyTreated (Safety Population)Cohort 1, Single-agent Dose-finding: Lenvatinib 17 mg/m^27
Overall StudyTreated (Safety Population)Cohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^21

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02432274/flow

API referenceFor AI assistants